NUTRIBAND INC (NTRB) Stock Price, Quote, News and Overview
NASDAQ:NTRB - Nasdaq - US67092M2089 - Common Stock - Currency: USD
NTRB Quote, Performance and Key Statistics
NUTRIBAND INC
NASDAQ:NTRB (1/23/2025, 9:21:48 PM)
After market: 10.19 +0.29 (+2.93%)9.9
+2.56 (+34.88%)
The current stock price of NTRB is 9.9 USD. In the past month the price increased by 142.65%. In the past year, price increased by 273.59%.
NTRB Latest News, Press Releases and Analysis
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
These stocks are moving in today's session
The trading volume of these stocks is deviating from the norm in today's session.
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
Nutriband Issues Letter to Shareholders
Nutriband Issues Letter to Shareholders
CEO Publishes Letter to Shareholders looking over achievements in 2024 and outlook for 2025...
Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology
NTRB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 75.38 | 727.75B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.21 | 360.19B | ||
| JNJ | JOHNSON & JOHNSON | 14.68 | 353.05B | ||
| MRK | MERCK & CO. INC. | 16.24 | 244.44B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.01 | 212.73B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.41 | 199.99B | ||
| PFE | PFIZER INC | 10.25 | 149.84B | ||
| SNY | SANOFI-ADR | 12.41 | 130.32B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 50.55 | 119.95B | ||
| ZTS | ZOETIS INC | 28.99 | 75.33B | ||
| GSK | GSK PLC-SPON ADR | 8.26 | 69.47B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.53 | 40.96B |
Related screens
About NTRB
Company Profile
Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. The company is headquartered in Orlando, Florida. The company went IPO on 2017-06-20. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. The company is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Company Info
NUTRIBAND INC
121 S Orange Ave Ste 1500
Orlando FLORIDA US
CEO: Gareth Sheridan
Employees: 13
Company Website: https://nutriband.com/
Investor Relations: http://www.nutriband.com/investors
Phone: 14073776695
NTRB FAQ
What is the price of NTRB?
The current price of NTRB is 9.9 USD.
What is the symbol for NUTRIBAND INC?
The exchange symbol of NUTRIBAND INC is NTRB and it is listed on the Nasdaq exchange.
On which exchange is NTRB listed?
NTRB is listed on the Nasdaq exchange.
Is NTRB a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for NTRB, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of NTRB.
Does NTRB pay dividends?
NTRB does not pay a dividend.
What is the Price/Earnings (PE) ratio of NTRB?
NTRB does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.71).
What is the Short Interest ratio of NTRB?
The outstanding short interest for NTRB is 2.2% of its float.
NTRB Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to NTRB. When comparing the yearly performance of all stocks, NTRB is one of the better performing stocks in the market, outperforming 98.21% of all stocks.
NTRB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NTRB. NTRB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NTRB Financial Highlights
Over the last trailing twelve months NTRB reported a non-GAAP Earnings per Share(EPS) of -0.71. The EPS increased by -6.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.59% | ||
| ROE | -60.96% | ||
| Debt/Equity | 0.01 |
NTRB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to NTRB. The Buy consensus is the average rating of analysts ratings from 7 analysts.